Organon & Company: New Leadership at May Health Amid Innovative PCOS Treatment Study
- May Health appoints Colby Holtshouse as President and CEO to lead the REBALANCE study for Ovarian Rebalancing™ technology.
- The innovative Ovarian Rebalancing™ procedure targets hormonal imbalances in PCOS, aiming for improved ovulation and recovery.
- May Health is committed to advancing women's health solutions through innovative research and development for PCOS treatments.
May Health Appoints New Leadership Amid Groundbreaking PCOS Study
May Health, a clinical-stage medical device company dedicated to addressing Polycystic Ovary Syndrome (PCOS), announces the appointment of Colby Holtshouse as President and CEO. With a strong background in women's health, Holtshouse's leadership is anticipated to steer the company during its pivotal REBALANCE study, designed to support marketing authorization for May Health's innovative Ovarian Rebalancing™ technology. This innovative procedure aims to treat PCOS, a condition affecting approximately 10% of women and a leading cause of infertility.
The Ovarian Rebalancing™ procedure employs a one-time, ultrasound-guided transvaginal ablation technique that utilizes radio frequency energy to target and ablate excess androgen-producing ovarian tissue. This targeted approach aims to restore ovulation in women who have not responded to traditional oral medications. By focusing on the underlying hormonal imbalances that contribute to PCOS, May Health's technology seeks to establish regular ovulatory menstrual cycles while ensuring a same-day recovery process that minimally disrupts a patient's daily life. Dr. Robert Auerbach, Chairman of May Health, emphasizes the importance of Holtshouse’s expertise as the company progresses through the clinical trial phase, which is crucial for obtaining regulatory approval.
As the REBALANCE study unfolds, the leadership transition comes at a critical time for May Health. The potential for Ovarian Rebalancing™ to revolutionize treatment options for millions of women suffering from PCOS-related infertility is significant. Industry experts, including Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, express optimism about the company's pioneering approach under Holtshouse’s guidance. The advancements in clinical evaluation and innovation resonate not only within the company but also across the broader women’s health landscape, highlighting a growing focus on addressing unmet medical needs in this area.
In addition to Holtshouse's appointment, May Health's ongoing commitment to advancing women's health solutions is reflected in its innovative research and development efforts. The company aims to bring forth treatments that go beyond traditional methods, promising improved outcomes and quality of life for women battling PCOS.
As May Health forges ahead with its clinical studies, the leadership change signals a broader movement within the medical community to embrace novel therapies for conditions that have long been inadequately addressed. The focus on PCOS not only sheds light on a significant women's health issue but also underscores the potential for transformative changes in treatment protocols and patient care in the near future.
